Download PDF Introduction The Consumer Healthcare sector has long been crucial for consumers to find quick solutions without heading to the doctors, covering over the counter (OTC) products such as supplements, medicines (painkillers), skincare, hygiene products, and more. With the rise of digital healthcare tools and prescription management, Consumer Healthcare Read more…
Download PDF Johnson & Johnson and its Competitors Johnson & Johnson (J&J) [NYSE: JNJ] is a US-based multinational healthcare corporation operating along its two segments Innovative Medicine and MedTech. Today (as of April 18th, 2024), the firm has a market capitalization of $351.2bn. In 2023, J&J recorded revenues of $85.2bn, Read more…
Download PDF Introduction Facing rising scrutiny from American activist investors, GlaxoSmithKline (GSK), Britain’s second-largest pharmaceutical company, is undertaking a major strategic shift. By spinning off its consumer healthcare division, and recently acquiring Sierra Oncology for $1.9bn, which is about to introduce a new blood cancer treatment to the market, GSK Read more…
Download PDF Introduction The pharmaceuticals sector has been the center of attention lately for the successful vaccines trial that finally gave some hope of recovery, even though it wasn’t without controversies. However, a lot more has been going on in the industry that might change the reputation that the industry Read more…
Introduction A persistent financial crisis, the rising of regional tensions, the concerns of a trade war and many other facts have recently been catching up with the M&A-friendly international environment. Protectionism seems now to pervade the new world order. Rising economic nationalism is threatening to impact M&A activity across all Read more…
Introduction M&A activity in 2015 has surpassed the peak from 2007 driven by deals in pharmaceuticals, energy, and consumer sector. Many of the factors that helped the dealmakers in 2015 are still in place, but the bond market turmoil and geopolitical instability might play a role in 2016 together with Read more…
Mylan N.V.; market cap as of 12/02/2016: $20.54bn Meda AB; market cap as of 12/02/2016: kr52.44bn ($6.24bn) Introduction On February 10, Mylan NV (NASDAQ: MYL.O) announced its acquisition of Meda AB (STO: MEDAa.ST) in a deal worth $7.2bn made of cash and stock, while the latter reported an unexpected slowdown Read more…
Pfizer Inc.; market cap as of 27/11/2015: $202.7bn Allergan plc; market cap as of 27/11/2015: $126bn Introduction On November 23, 2015, Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) announced that their boards of directors have unanimously approved a definitive merger agreement under which Pfizer will combine with Read more…
Teva Pharmaceutical Industries ; Market Cap (as of 25/04/2015): $62,67bn Mylan Pharmaceuticals ; Market Cap (as of 25/04/2015): $36,06bn Introduction In the healthcare industry, the saying “eat or be eaten” no longer applies. Instead, the adage of “make a bid or wait for an offer” would be more appropriate Read more…
Pfizer Inc.; market cap (as of 20/02/2015): US$217.75bn Hospira Inc.; market cap (as of 20/02/2015): US$14.97bn Introduction On February 5th, 2014, pharmaceutical behemoth Pfizer signed with Hospira, the world’s leading provider of injectable drugs and biosimilars, a definitive merger agreement which consists of the fully acquisition of Hospira for US$90 Read more…
Pfizer Inc, Market Cap (as of 23/05/2014): $188.37bn AstraZeneca PLC, Market Cap (as of 23/05/2014): $91.78bn In its bid for AstraZeneca, Pfizer, the famous Viagra producer, failed to make a satisfactory offer and turned the potential biggest foreign takeover in UK corporate history into failure. It all happened on May Read more…